ReviewToxins2020
The Pharmacological Mechanism of Diabetes Mellitus-Associated Overactive Bladder and Its Treatment with Botulinum Toxin A.
Review in Toxins, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed, 1 synthesis or guideline pooled it, 29 citations in OpenAlex.
- Pooled it
- The Real Impact of De Novo Bladder Dysfunction After Transvaginal Tension-Free Vaginal Tape-Obturator (TVT-O): A Prospective Study.Journal of clinical medicine · 2026Article
- Efficacy of bilateral sacral neuromodulation in treating neurogenic bladder and bowel dysfunction.Translational andrology and urology · 2026Article
- Associations of estimated glucose disposal rate and overactive bladder and the potential mediating role of systemic inflammation: NHANES 2005-2018.Diabetology & metabolic syndrome · 2026Article
- Article
- Therapeutic Potential of Mitochondrial Transplantation with Focus on DBD.International journal of molecular sciences · 2026Review
- Clinical predictors of symptom and quality-of-life improvement with antimuscarinics in overactive bladder: a 12-month prospective cohort study in Türkiye.BMC urology · 2026Observational
- Association between dietary intake of fatty acids, central obesity, and OAB: insights from a prospective cohort for weight management and dietary prevention.Therapeutic advances in endocrinology and metabolism · 2026Article
- Association of albumin-corrected anion gap with all-cause and cardiovascular mortality in overactive bladder patients.Scientific reports · 2025Article
- Associations between chrono-nutrition and chronic kidney disease, urinary incontinence and kidney stones: a cross-sectional study.Preventive medicine reports · 2025Article
- Association between magnesium depletion score and overactive bladder among U.S. Adults using data from NHANES 2005-2018.Scientific reports · 2025Article
- A female overactive bladder risk model developed by machine learning: based on 2007-2018 NHANES data.Translational andrology and urology · 2025Article
- Mediating role of SII in the association between LC9 and overactive bladder.Scientific reports · 2025Article
- Predicting overactive bladder from inflammatory markers: A machine learning approach using NHANES 2005-2020.Biomolecules & biomedicine · 2025Article
- Role and mechanism of Roux-en-Y gastric bypass in the treatment of diabetic urinary bladder hyperactivity by reducing TRPV1 and P2X3.World journal of diabetes · 2025Article
- The association between overactive bladder and systemic immunity-inflammation index: a cross-sectional study of NHANES 2005 to 2018.Scientific reports · 2024Article
- Association between life's essential 8 and overactive bladder.Scientific reports · 2024Article
- Association of healthy eating index-2015 and overactive bladder: a cross-sectional study.Frontiers in nutrition · 2024Article
- Diabetes mellitus, systemic inflammation and overactive bladder.Frontiers in endocrinology · 2024Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Diabetes mellitus (DM) is an independent risk factor for overactive bladder (OAB). The pathophysiology of DM-associated OAB is multifactorial and time-dependent. Diabetic bladder dysfunction is highly associated with diabetic complications, mainly including diabetic neuropathy and atherosclerosis. Chronic systemic inflammation and bladder urothelial inflammation may contribute to the onset of OAB. Intravesical botulinum toxin A (BoNT-A) injection has proved to be a successful treatment for idiopathic and neurogenic OAB. BoNT-A can inhibit the efferent pathways of the bladder as well as the chronic inflammation and hypersensitivity via the afferent pathways. We conducted a review of the published literature in Pubmed using a combination of two keywords, namely "botulinum toxin A" (BoNT-A) and "overactive bladder", with or without the additional keywords "detrusor overactivity", "diabetes mellitus", "inflammation", and "urodynamic study". We also reviewed the experience of our research teams, who have published several studies of the association between DM and OAB. Since limited data support the effectiveness and safety of BoNT-A for treating patients with DM-associated OAB, a comprehensive evaluation of diabetic complications and urodynamic study is needed before treatment. In the future, it is imperative to explore the clinical characteristics and inflammatory biomarkers of diabetes as determining predictors of the treatment efficacy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.